Anetholethio Tablets
Function and Efficacy
1. Pharmacological action This product can significantly increase the number of muscarinic receptors and significantly increase the secretion of glands (salivary glands and lacrimal glands). It has a significant therapeutic effect on the dryness symptoms of primary Sjǒgren syndrome (i.e. dry mouth, eye and nose syndrome), and can significantly improve the symptoms of dry mouth, dry eyes, dry nose and dry vaginal mucosa. It can antagonize the inhibition of salivary gland secretion caused by M receptor antagonists such as atropine, and correct drug-induced dry mouth caused by taking certain drugs (antihypertensive drugs, diuretics, tranquilizers, sedatives, antidepressants, anti-Parkinson's disease drugs, etc.) and dry mouth caused by radiotherapy in the oropharyngeal area. 2. Toxicology studies The median lethal dose (LD50) of the drug for oral administration and intraperitoneal injection in mice was 3740.38 mg/kg (95% confidence limit: 2397.76-5834.79 mg/kg) and 1685.69 mg/kg (95% confidence limit: 1214.29-2340.09 mg/kg), respectively.
Ingredients
The main ingredient of this product is anethiol.
| Name | Description | Content | CAS NO. | Manufacturer |
|---|---|---|---|---|
| Anethole trithioneIngredients |
It can significantly increase the number of muscarinic receptors and the secretion of glands (salivary glands and lacrimal glands). It has a significant therapeutic effect on the dryness symptoms of primary Sjǒgren syndrome (i.e. dry mouth, eye and nose syndrome), and can significantly improve the symptoms of dry mouth, dry eyes, dry nose and dry vaginal mucosa. It can antagonize the inhibition of salivary gland secretion caused by M receptor antagonists such as atropine, and correct drug-induced dry mouth caused by taking certain drugs (antihypertensive drugs, diuretics, tranquilizers, sedatives, antidepressants, anti-Parkinson's disease drugs, etc.) and dry mouth caused by radiotherapy in the oropharyngeal area. More |
532-11-6 | 11 |
Appearance
This product is a film-coated tablet. After removing the film coating, it appears orange-yellow.
Indication
Used for cholecystitis, gallstones and digestive discomfort, and as an auxiliary treatment for acute and chronic hepatitis.
Usage and Dosage
Oral administration. 3 times a day, 1 tablet each time, or as directed by your doctor.
Adverse Reactions
Urticarial erythema occasionally occurs.
Precautions
1. It is contraindicated for patients with complete bile duct obstruction. 2. It is contraindicated for patients who are allergic to this product.
Special Population Medication
Precautions for children: Lack of clinical drug data, children should use with caution Precautions for pregnancy and lactation: Forbidden. Precautions for the elderly: This product is mainly metabolized by the liver. The elderly have low liver function, which leads to a higher concentration of the drug in the blood. Therefore, elderly patients should take a reduced dose as appropriate (e.g. 37.5 mg/day).
Drug Interactions
Not yet clear.
Storage
Keep away from light and store in a sealed container.
Packaging Specification
25mg
Validity Period
Tentative 36 months
Manufacturer
Shandong Bausch & Lomb Freda Pharmaceutical Co., Ltd.
-
Founded in:
1992-03-31 -
Address:
No. 789, Xinluo Street, Jinan High-tech Development Zone -
Tax NO.:
913701006140705563 -
Registered Funds:
90 million yuan -
Website:
-
Email: